Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
CNS Pharmaceuticals, Inc. CNSP
$1.36
-$0.08 (-5.56%)
На 18:02, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
3606637.00000000
-
week52high
11.31
-
week52low
0.61
-
Revenue
0
-
P/E TTM
0
-
Beta
1.10934200
-
EPS
-10.59000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 20:00
Описание компании
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Brookline Capital | Buy | 02 февр 2021 г. | |
| Ladenburg Thalmann | Buy | 24 авг 2020 г. | |
| Benchmark | Speculative Buy | 04 дек 2019 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Charles Faith L. | A | 3500 | 3500 | 30 дек 2022 г. |
| Climaco John M | A | 1349500 | 600000 | 28 апр 2022 г. |
| Downs Christopher | A | 681000 | 250000 | 28 апр 2022 г. |
| Downs Christopher | A | 184500 | 33000 | 11 мар 2022 г. |
| Evans Carl Anthony | A | 3750 | 3750 | 08 мар 2022 г. |
| Keyes Jeffry R. | A | 11100 | 11100 | 07 мар 2022 г. |
| Climaco John M | A | 940298 | 35000 | 07 мар 2022 г. |
| Downs Christopher | A | 151500 | 5000 | 06 дек 2021 г. |
| Downs Christopher | A | 146500 | 4500 | 19 ноя 2021 г. |
| Climaco John M | A | 905298 | 5000 | 16 ноя 2021 г. |
Новостная лента
CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event
PRNewsWire
05 янв 2023 г. в 09:05
Live video webcast on Wednesday, January 18 th at 10:00 AM ET HOUSTON , January 5, 2023 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the Virtual Investor 2023 Companies to Watch Event on Wednesday, January 18, 2023 at 10:00 AM ET. A live video webcast of the presentation will be available on the Events page of the Investors section of the Company's website (cnspharma.com).
CNS Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
PRNewsWire
07 сент 2022 г. в 08:45
HOUSTON , Sept. 7, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco , Chief Executive Officer of CNS Pharmaceuticals, will present at the H.C.